Halozyme Therapeutics (NASDAQ:HALO) posted its earnings results on Tuesday. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.05), Briefing.com reports. Halozyme Therapeutics had a negative net margin of 23.53% and a negative return on equity of 16.97%. The business had revenue of $46.20 million for the quarter, compared to analyst estimates of $54.96 million. During the same quarter last year, the business earned ($0.19) earnings per share. Halozyme Therapeutics’s revenue was up 80.5% on a year-over-year basis.
Shares of NASDAQ:HALO traded up $0.24 during trading on Wednesday, hitting $17.01. The company’s stock had a trading volume of 109,799 shares, compared to its average volume of 870,738. The business has a 50 day moving average price of $15.73 and a two-hundred day moving average price of $16.14. The company has a market capitalization of $2.47 billion, a PE ratio of -30.38 and a beta of 1.78. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.57 and a current ratio of 2.89. Halozyme Therapeutics has a fifty-two week low of $13.24 and a fifty-two week high of $17.79.
A number of brokerages recently weighed in on HALO. BidaskClub lowered shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, September 27th. Zacks Investment Research raised shares of Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating and set a $18.00 target price on the stock in a research note on Thursday, November 7th. ValuEngine lowered shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, October 21st. Finally, Barclays raised shares of Halozyme Therapeutics from an “underweight” rating to an “equal weight” rating and reduced their price target for the company from $17.00 to $16.00 in a research report on Tuesday, November 5th. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $20.50.
Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Featured Article: Moving Average (MA)
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.